 The underlying scientific hypothesis is based on data from the NEOSPHERE neoadjuvant trial showing that addition of pertuzumab to trastuzumab plus docetaxel improved the pCR rate 46 versus 29 without pertuzumab in T2-T3 tumors. Therefore, we hypothesize that for smaller tumors T1c, the pCR rate should be higher, on the order of 60 in patients with the coamplification with anthracycline therapy and 55 for the group without coamplification without anthracycline therapy. The sample size of 90 patients 45 per group planned for the phase II study will allow 15 precision with the expected pCR rates of 60 95CI: 45-75 for patients with coamplification and 55 95CI: 40-70 for those without coamplification. In addition, exploratory analyses will aim to identify predictive markers of pCR in order to target biologically defined subpopulations in which pCR rates might even be higher. 